Sign In
Buy CPRX
$31.28
+0.0100 (+0.0320%)
At Close: Jun 03, 2026
Catalyst Pharmaceuticals, Inc. (CPRX) Q3 2022 Earnings Call Transcript
02:34pm, Thursday, 10'th Nov 2022
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX ) Q3 2022 Earnings Conference Call November 10, 2022 8:30 AM ET Company Participants Ali Grande - Chief Financial Officer Patrick McEnany - Chairman and Chi
Catalyst Pharmaceutical (CPRX) Tops Q3 Earnings and Revenue Estimates
10:35pm, Wednesday, 09'th Nov 2022 Zacks Investment Research
Catalyst (CPRX) delivered earnings and revenue surprises of 5.26% and 6.40%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Catalyst Pharmaceuticals Reports Record Third Quarter 2022 Financial Results and Provides a Corporate Update
09:11pm, Wednesday, 09'th Nov 2022 GlobeNewswire Inc.
Achieved Record Q3 2022 FIRDAPSE® Net Revenue of $57.2 Million, a 59.3% YoY Increase
Catalyst Pharmaceutical (CPRX) Tops Q3 Earnings and Revenue Estimates
06:48pm, Wednesday, 09'th Nov 2022
Catalyst (CPRX) delivered earnings and revenue surprises of 5.26% and 6.40%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Catalyst Pharmaceuticals (CPRX) to Post Q3 Earnings: What's Up?
08:08pm, Monday, 07'th Nov 2022 Zacks Investment Research
On Catalyst Pharmaceuticals' (CPRX) third-quarter earnings call, investors will likely focus on the sales performance of Firdapse approved for treating LEMS.
Catalyst Pharmaceuticals (CPRX) to Post Q3 Earnings: What's Up?
04:33pm, Monday, 07'th Nov 2022
On Catalyst Pharmaceuticals' (CPRX) third-quarter earnings call, investors will likely focus on the sales performance of Firdapse approved for treating LEMS.
Catalyst Pharmaceuticals Named BioFlorida 2022 Company of the Year
01:03pm, Monday, 07'th Nov 2022 GlobeNewswire Inc.
CORAL GABLES, Fla., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, a
Strength Seen in Alpine Immune Sciences, Inc. (ALPN): Can Its 7.5% Jump Turn into More Strength?
08:46am, Friday, 04'th Nov 2022 Zacks Investment Research
Alpine Immune Sciences, Inc. (ALPN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in t
Biotech Stock Catalyst Pharmaceuticals Offers Buy Point Ahead Of Earnings
02:26pm, Thursday, 03'rd Nov 2022
Catalyst Pharmaceuticals approaches a buy point with earnings due. Stellar ratings support the price action.
Catalyst Pharmaceuticals to Report Third Quarter 2022 Financial Results on November 9, 2022
12:03pm, Tuesday, 25'th Oct 2022 GlobeNewswire Inc.
Conference Call and Webcast to be held on November 10, 2022, at 8:30 AM ET Conference Call and Webcast to be held on November 10, 2022, at 8:30 AM ET
Catalyst Pharmaceuticals to Report Third Quarter 2022 Financial Results on November 9, 2022
08:03am, Tuesday, 25'th Oct 2022
Conference Call and Webcast to be held on November 10, 2022, at 8:30 AM ET Conference Call and Webcast to be held on November 10, 2022, at 8:30 AM ET
Talaris (TALS) Down on Patient Death From Renal Transplant Study
03:28pm, Friday, 21'st Oct 2022 Zacks Investment Research
Talaris Therapeutics (TALS) reports a patient death from its late-stage study evaluating its experimental drug, FCR001, in living donor kidney transplant patients. Stock down.
These 3 Stocks Are Winning the Bear Market -- Here's How
01:30pm, Friday, 21'st Oct 2022 The Motley Fool
Picking the right markets to compete in makes surviving bear markets much more manageable for these companies.
Zacks Industry Outlook Highlights Jazz Pharmaceuticals, Catalyst Pharmaceuticals, Aerie Pharmaceuticals, Larimar Therapeutics and Fusion Therapeutics
09:35am, Friday, 21'st Oct 2022 Zacks Investment Research
Jazz Pharmaceuticals, Catalyst Pharmaceuticals, Aerie Pharmaceuticals, Larimar Therapeutics and Fusion Therapeutics have been highlighted in this Industry Outlook article.
RedHill Biopharma (RDHL) Up on New Patent for COVID-19 Candidate
05:08pm, Thursday, 20'th Oct 2022 Zacks Investment Research
RedHill Biopharma (RDHL) receives a new patent from the United States Patent and Trademark Office for its investigational COVID-19 candidate, opaganib, in COVID-19 patients with pneumonia. Stock up.
